Srinivas Ganta1, Amit Singh2, Yashesh Rawal3, Joseph Cacaccio1,3, Niravkumar R Patel1, Praveen Kulkarni4,5, Craig F Ferris4,5, Mansoor M Amiji2,5, Timothy P Coleman1,3,5,6. 1. a Nemucore Medical Innovations, Inc. , Worcester , MA , USA . 2. b Department of Pharmaceutical Sciences , School of Pharmacy, Northeastern University , Boston , MA , USA . 3. c Blue Ocean Biomanufacturing, Inc. , Worcester , MA , USA . 4. d Center for Translational Imaging, Northeastern University , Boston , MA , USA . 5. e Center for Translational Cancer Nanomedicine Northeastern University , Boston , MA , USA , and. 6. f Foundation for the Advancement of Personalized Medicine Manufacturing , Phoenix , AZ , USA.
Abstract
OBJECTIVE: Ovarian cancer is a highly lethal disease in which the majority of patients eventually demonstrate multidrug resistance. Develop a novel active targeted theranostic nanomedicine designed to overcome drug efflux mechanisms, using a Generally Regarded As Safe (GRAS) grade nanoemulsion (NE) as a clinically relevant platform. MATERIALS AND METHODS: The NEs surface-functionalized with folate and gadolinium, were made using GRAS grade excipients and a high-shear microfluidization process. Efficacy was evaluated in ovarian cancer cells, SKOV3 and SKOV3TR. The NE accumulation in tumors was evaluated in SKOV3 tumor-bearing mice by magnetic resonance imaging (MRI). RESULTS AND DISCUSSION: The NE with particle size < 150 nm were stable in plasma and parenteral fluids for 24 h. Ovarian cancer cells in vitro efficiently took up the non-targeted and folate-targeted NEs; improved cytotoxicity was observed for the folate-targeted NEs showing a 270-fold drop in the IC50 in SKOV3TR cells as compared to docetaxel alone. The addition of gadolinium did not affect cell viability in vitro, but showed relaxation times comparable to Magnevist®. Folate-targeted NEs accumulated in tumors for prolonged period of time compared to Magnevist® and showed enhanced contrast compared to non-targeted NEs with MRI in SKOV3 tumor-bearing mice suggesting active targeting of NEs due to folate modification. CONCLUSIONS: A folate-targeted, theranostic NE delivers docetaxel by receptor mediated endocytosis that shows enhanced cytotoxicity capable of overcoming ABC transporter mediated taxane resistance. The diagnostic capability of the targeted nanomedicine showed enhanced contrast in tumors compared to clinically relevant MRI contrast agent Magnevist®.
OBJECTIVE:Ovarian cancer is a highly lethal disease in which the majority of patients eventually demonstrate multidrug resistance. Develop a novel active targeted theranostic nanomedicine designed to overcome drug efflux mechanisms, using a Generally Regarded As Safe (GRAS) grade nanoemulsion (NE) as a clinically relevant platform. MATERIALS AND METHODS: The NEs surface-functionalized with folate and gadolinium, were made using GRAS grade excipients and a high-shear microfluidization process. Efficacy was evaluated in ovarian cancer cells, SKOV3 and SKOV3TR. The NE accumulation in tumors was evaluated in SKOV3tumor-bearing mice by magnetic resonance imaging (MRI). RESULTS AND DISCUSSION: The NE with particle size < 150 nm were stable in plasma and parenteral fluids for 24 h. Ovarian cancer cells in vitro efficiently took up the non-targeted and folate-targeted NEs; improved cytotoxicity was observed for the folate-targeted NEs showing a 270-fold drop in the IC50 in SKOV3TR cells as compared to docetaxel alone. The addition of gadolinium did not affect cell viability in vitro, but showed relaxation times comparable to Magnevist®. Folate-targeted NEs accumulated in tumors for prolonged period of time compared to Magnevist® and showed enhanced contrast compared to non-targeted NEs with MRI in SKOV3tumor-bearing mice suggesting active targeting of NEs due to folate modification. CONCLUSIONS: A folate-targeted, theranostic NE delivers docetaxel by receptor mediated endocytosis that shows enhanced cytotoxicity capable of overcoming ABC transporter mediated taxane resistance. The diagnostic capability of the targeted nanomedicine showed enhanced contrast in tumors compared to clinically relevant MRI contrast agent Magnevist®.
Authors: Ronan J Kelly; Deborah Draper; Clara C Chen; Robert W Robey; William D Figg; Richard L Piekarz; Xiaohong Chen; Erin R Gardner; Frank M Balis; Aradhana M Venkatesan; Seth M Steinberg; Tito Fojo; Susan E Bates Journal: Clin Cancer Res Date: 2010-11-16 Impact factor: 12.531
Authors: Jing Li; Edward A Sausville; Patrick J Klein; David Morgenstern; Christopher P Leamon; Richard A Messmann; Patricia LoRusso Journal: J Clin Pharmacol Date: 2009-10-16 Impact factor: 3.126
Authors: Ronald E Fisher; Barry A Siegel; Steven L Edell; Nelson M Oyesiku; David E Morgenstern; Richard A Messmann; Robert J Amato Journal: J Nucl Med Date: 2008-05-15 Impact factor: 10.057
Authors: Paul Ruff; D A Vorobiof; J P Jordaan; G S Demetriou; S D Moodley; A L Nosworthy; I D Werner; J Raats; L J Burgess Journal: Cancer Chemother Pharmacol Date: 2009-02-25 Impact factor: 3.333
Authors: Niravkumar R Patel; Aleksandr Piroyan; Srinivas Ganta; Allison B Morse; Katie M Candiloro; April L Solon; Abbegail H Nack; Corin A Galati; Collete Bora; Marisa A Maglaty; Shane W O'Brien; Samuel Litwin; Barbara Davis; Denise C Connolly; Timothy P Coleman Journal: Cancer Biol Ther Date: 2018-05-08 Impact factor: 4.742
Authors: Srinivas Ganta; Amit Singh; Praveen Kulkarni; Amanda W Keeler; Aleksandr Piroyan; Rupa R Sawant; Niravkumar R Patel; Barbara Davis; Craig Ferris; Sara O'Neal; William Zamboni; Mansoor M Amiji; Timothy P Coleman Journal: Pharm Res Date: 2015-03-04 Impact factor: 4.200
Authors: Noor Hafizah Arbain; Norazlinaliza Salim; Hamid Reza Fard Masoumi; Tin Wui Wong; Mahiran Basri; Mohd Basyaruddin Abdul Rahman Journal: Drug Deliv Transl Res Date: 2019-04 Impact factor: 4.617